# Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

> **NCT01833143** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Acyclovir

## Key facts

- **NCT ID:** NCT01833143
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-11
- **Primary completion:** 2019-08-28
- **Final completion:** 2019-08-28
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833143, "Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01833143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*